The first nonhormonal drug for hot flashes associated with menopause was approved by the US Food and Drug Administration (FDA) today despite an agency advisory committee having rejected it as too much ...
The US Food and Drug Administration's (FDA's) expert panel on reproductive health drugs has voted against approval of 2 nonhormonal options for the treatment of moderate to severe vasomotor symptoms ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO, Fla. — During an abstract session at the North American Menopause Society 23rd Annual Meeting, ...
Noven Pharmaceuticals announced results from two multicenter, double-blind, randomized, placebo-controlled Phase 3 clinical studies evaluating low-dose mesylate salt of paroxetine (LDMP) for the ...
Noven Pharmaceuticals announced that it has submitted a New Drug Application (NDA) for low-dose mesylate salt of paroxetine (LDMP) to the FDA, seeking approval for the treatment of vasomotor symptoms ...
The Food and Drug Administration has given the go-ahead for Brisdelle, a non-hormonal drug that aims to relieve hot flashes. If hot flashes are driving you wild, the U.S. Food and Drug Administration ...
(Reuters) - Food and Drug Administration staff said experimental drugs by Depomed Inc and Hisamitsu Pharmaceutical Co Inc showed efficacy in reducing menopausal hot flashes, and highlighted no new ...
WACO, Texas (Aug. 29, 2023) – Hot flashes are one of the most concerning and most reported symptoms among menopausal women and breast cancer survivors. Currently, paroxetine is a FDA-approved ...
The U.S. Food and Drug Administration has granted final approval to a Synthon Pharmaceuticals Ltd. product that the company bills as an alternative to GlaxoSmithKline's Paxil. The FDA granted approval ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback